Evidence map›Paper›PMID 41146519›Full record

ReviewClinical and molecular hepatology2026

Incretin-based therapies for cardio-kidney-liver-metabolic disease: the role of the liver in the modern era of chronic disease management.

Harendran Elangovan, Rohit Loomba, Mark Muthiah, Jörn Schattenberg, Ming Hua Zheng, Mazen Noureddin, Christos Mantzoros, Jacob George

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Clinical and molecular hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Harendran ElangovanStorr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital and The University of Sydney, Westmead, NSW, Australia.
Rohit LoombaMASLD Research Center, University of California San Diego, San Diego, CA, USA.
Mark MuthiahDivision of Gastroenterology and Hepatology, Department of Medicine, National University Hospital, Singapore.
Jörn SchattenbergSaarland University Medical Center, University of the Saarland, Homburg, Germany and PharmaScienceHub (PSH), Saarbrücken, Germany.
Ming Hua ZhengMAFLD Research Center, Department of Hepatology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Mazen NoureddinDivision of Gastroenterology and Hepatology, Houston Methodist Hospital, Houston, TX, USA.
Christos MantzorosDepartment of Medicine, Division of Endocrinology, Beth Israel Hospital, Harvard Medical School, Boston, MA, USA.
Jacob GeorgeStorr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital and The University of Sydney, Westmead, NSW, Australia.

Funding

89 BioAligosAmgenAnsh IncAstra ZenecaBMSBoehringer ManheimBoston Scientific CorporationCancer Institute, NSW 2021/ATRG2028Cardio Metabolic Health ConferenceCinceraCorceptCSLEisaiElsevier FoundationGilead FoundationInterceptLabCorp IncMadrigalMRFF APP1196492MRFF APP2010795MRFF APP2016215MRFF APP2032407MRFF NCRI000183National Health and Medical Research Council APP1053206NestleNorgineNovo NordiskOlympus MedicalPfizerPharmaxisRegeneronRocheRoche and AstellasTMIOAUniversity of Sydney
6 · The paper itself

Abstract

Steatotic liver disease (SLD) is a leading cause of disease globally and demands new therapeutic approaches to mitigate underlying metabolic dysregulation. Incretin-based therapies are emerging as a viable prospect to fulfil this unmet niche. A literature review to inform the evidence base for incretin focussed pharmacology in the metabolic liver diseases space and an informed commentary on unmet areas of need. Incretin-based therapeutics demonstrate multifarious benefits across the chronic metabolic disease spectrum with promising data across the continuum of pathology.

Indexed as

Heart DiseasesIncretinsKidney DiseasesLiver DiseasesMetabolic DiseasesCardiovascular DiseasesChronic DiseaseDipeptidyl-Peptidase IV InhibitorsFatty LiverHumansLiverDipeptidyl-Peptidase IV InhibitorsIncretinsCKLMGIPGLP-1GlucagonIncretinsMAFLDMASH

Identifiers

PMID41146519
PMCPMC12835728

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.